DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...
DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
Zacks Investment Research on MSN
Countdown to DexCom (DXCM) Q4 earnings: Wall Street forecasts for key metrics
Wall Street analysts forecast that DexCom (DXCM) will report quarterly earnings of $0.65 per share in its upcoming release, pointing to a year-over-year increase of 44.4%. It is anticipated that ...
This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...
DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results